The most significant limitations are the sample size of the study and the inclusion of only one leptin gene polymorphism in the analysis, which does not fully characterize the entire aspect of the clinical phenotype of a patient with severe and difficult-to-control asthma associated with metabolic syndrome. This evidence concerns the gene LEP and metabolic syndrome.